Streetbeat News

Regulatory

HMC

Honda Motor (HMC) plans to produce its next Civic hybrid in Indiana instead of Mexico to avoid potential tariffs, as reported by Reuters.

Portfolio Pulse from

March 03, 2025 | 7:15 pm

PCMM

Joanna Gallegos, co-founder and COO of Bondbloxx, discusses the use of private credit and private equity in ETFs on CNBC's 'Halftime Report'. The conversation touches on the controversy surrounding these financial products.

Portfolio Pulse from

March 03, 2025 | 6:45 pm

NVDA

Nvidia shares fell over 7% following a report that Chinese buyers are bypassing US export controls to acquire its latest chips. The Wall Street Journal reported that Chinese traders are obtaining Nvidia's Blackwell chips through third parties in nearby regions.

Portfolio Pulse from

March 03, 2025 | 6:30 pm

RKLB

Levi & Korsinsky has initiated an investigation into Rocket Lab USA, Inc. (RKLB) for potential securities fraud. This follows a report by Bleecker Street Research alleging that Rocket Lab misled investors about the launch timeline of its Neutron rocket.

Portfolio Pulse from

March 03, 2025 | 6:30 pm

MP

MP Materials CEO James Litinsky discusses concerns over China's potential AI advantage as a U.S.-Ukraine mineral deal stalls. The deal involves critical rare earths essential for AI and defense sectors.

Portfolio Pulse from

March 03, 2025 | 6:30 pm

TSM

TSMC plans to invest $100 billion in the U.S. over the next four years, with an announcement expected at the White House. This significant investment highlights TSMC's commitment to expanding its semiconductor manufacturing capabilities in the U.S.

Portfolio Pulse from

March 03, 2025 | 6:00 pm

HMC

Honda is shifting its Civic production from Mexico to Indiana in response to Trump's proposed 25% tariffs on Mexico and Canada. This move aligns with other companies considering US manufacturing to avoid tariffs.

Portfolio Pulse from

March 03, 2025 | 6:00 pm

HMC

Japanese automakers may benefit from Trump's trade policies due to their strong trade diplomacy skills, which could help mitigate tariffs.

Portfolio Pulse from

March 03, 2025 | 5:45 pm

KRYS

Krystal Biotech has received a positive opinion from the CHMP recommending the approval of its drug Vyjuvek for the treatment of dystrophic epidermolysis bullosa in the EU.

Portfolio Pulse from

March 03, 2025 | 5:15 pm